Background
Celgene was invited to submit evidence for this single technology appraisal for paclitaxel as albumin‑bound nanoparticles in September 2015.
The company stated that it does not intend to launch paclitaxel as albumin‑bound nanoparticles with carboplatin for untreated non‑small‑cell lung cancer when potentially curative surgery or radiation therapy or both are unsuitable, in the UK.
NICE has therefore terminated this single technology appraisal.